If you are preparing a Baxalta US Inc. lawsuit, the defendant you name is one of two related Delaware entities (Baxalta US Inc. or its former parent Baxalta Incorporated), and the company standing behind either one today is Takeda Pharmaceutical Company, which inherited Baxalta’s liabilities through a chain of statutory mergers.
Which Baxalta Entity to Name
Baxalta Incorporated and Baxalta US Inc. are not the same company. Baxalta Incorporated was the Delaware-incorporated parent, publicly traded on the New York Stock Exchange during its short period of independence.1U.S. Securities and Exchange Commission. Baxalta Incorporated Prospectus Baxalta US Inc. was a subsidiary of that parent and appears in federal court records, including patent litigation in the District of Delaware, as its own legal entity. Both now sit inside Takeda’s corporate structure.
The distinction matters. Naming the wrong entity creates problems with service of process and personal jurisdiction, and it can send a case sideways before anyone reaches the merits. Court filings have listed Baxalta Incorporated and Baxalta US Inc. as co-parties, which confirms they can be sued separately. Before filing, verify through the Delaware Division of Corporations or the SEC’s EDGAR database which entity actually manufactured, distributed, or held the product license at issue in your case.
Why Takeda Now Stands Behind the Claim
Baxalta was spun off from Baxter International on July 1, 2015.2Baxter International Inc. Baxter Board of Directors Approves Separation of Baxalta Shire plc acquired it on June 3, 2016, through a reverse merger in which a Shire subsidiary merged into Baxalta and Baxalta survived as a wholly-owned Shire subsidiary.3U.S. Securities and Exchange Commission. Shire-Baxalta Merger Registration Statement S-4/A Takeda then acquired Shire on January 8, 2019, and Baxalta and Shire both became wholly-owned Takeda subsidiaries.4Takeda Pharmaceutical Company. Takeda Announces Baxalta Consent Solicitation
Both acquisitions were statutory mergers, not asset purchases. Under Delaware law, when a merger takes effect the surviving corporation inherits every debt, liability, and duty of each constituent corporation, enforceable against the survivor as if it had incurred them itself, with creditors’ rights and liens preserved.5Delaware Code Online. Delaware Code Title 8 Chapter 1 Subchapter IX – Merger or Consolidation No assumption agreement is required. No court has to weigh whether an exception applies.
The four familiar exceptions to successor liability (express assumption, de facto merger, mere continuation, and fraudulent transfer) exist for asset sales, where a buyer takes property without merging with the seller. That framework does not do the work here. Because Shire’s acquisition of Baxalta and Takeda’s acquisition of Shire were both mergers, liability moved by operation of law each time. A claimant does not need to prove any exception to reach Takeda; the mergers already accomplished the transfer.
If the Product Predates July 1, 2015
Claims tied to products manufactured or sold before the 2015 spin-off are more complicated. The separation between Baxter and Baxalta was governed by a Separation and Distribution Agreement filed with the SEC, which allocated assets and liabilities between the two companies.6U.S. Securities and Exchange Commission. Baxter-Baxalta Separation and Distribution Agreement Baxalta’s SEC filings describe its “historical business and operations” as the biopharmaceuticals business transferred from Baxter in the separation.1U.S. Securities and Exchange Commission. Baxalta Incorporated Prospectus
The agreement released each party from liabilities assigned to the other. Practically, claims tied to Baxalta’s therapeutic areas (hematology, immunology, biotherapeutics, oncology) likely follow Baxalta and therefore rest with Takeda today. Claims tied to products that stayed with Baxter’s medical devices and renal care business likely stay with Baxter. Which side of the line your product falls on depends on the specific allocation language, which is available through EDGAR and should be reviewed before you name a defendant.
Products That Anchor Most Claims
Baxalta’s portfolio focused on treatments for rare and serious conditions. Identifying the specific product matters because liability attaches to it and to the entity responsible for it.
- Hematology: ADVATE and ADYNOVATE for hemophilia A, FEIBA for hemophilia patients with inhibitors, and OBIZUR for acquired hemophilia A.
- Immunology: GAMMAGARD LIQUID and HYQVIA, immunoglobulin therapies for primary immunodeficiency disorders.
- Biotherapeutics: FLEXBUMIN (albumin) and ARALAST NP for alpha-1 antitrypsin deficiency.
- Oncology: ONCASPAR for acute lymphoblastic leukemia.
Many of Baxalta’s products are biologics derived from human plasma or recombinant proteins, and injuries linked to biologics can surface years or decades after use. Hemophilia treatments in particular have a long litigation history reaching back to blood-derived factor products linked to HIV and hepatitis C transmission. Modern recombinant products carry different risk profiles, but the long tail of biologic therapy claims is one reason lawsuits continue to be filed against successor entities. Today, those defenses are handled by Takeda’s legal team regardless of whether the product was sold during the Baxter era, Baxalta’s brief independence, the Shire years, or under Takeda itself.
Deadlines That Quietly End Claims
Two different clocks limit when you can file.
The statute of limitations runs from when the injury is discovered or reasonably should have been discovered. In pharmaceutical product liability, this period commonly runs two to four years depending on the state. A discovery rule can extend the deadline when harm surfaces late, but defendants often argue that a plaintiff should have connected the dots sooner, so the timeline of symptoms and diagnosis needs to be documented carefully.
The statute of repose is a harder cutoff. It runs from a fixed event, usually the date the product was sold or first delivered, and it generally cannot be tolled for late discovery. Repose periods commonly run five to fifteen years depending on the state. For products sold during the Baxter era before 2015, some state repose periods may already have expired, cutting off otherwise valid claims. This is the single most common reason strong cases are dismissed, and delay is what causes it.
Serving the Right Entity in the Right Place
Service of process is enforced strictly, and a mistake here can dismiss a case before anything else happens. Because Baxalta Incorporated is a Delaware corporation, its registered agent for service of process is maintained in Delaware. Delaware’s Division of Corporations runs a searchable entity database where the current registered agent can be verified before you serve.
Takeda’s U.S. operations are headquartered in Cambridge, Massachusetts.7Takeda Pharmaceutical Company. Main Addresses Baxalta Incorporated’s historical principal business address was 1200 Lakeside Drive, Bannockburn, Illinois, but that address should not be relied on for service today. Verify the current registered agent through Delaware’s entity search rather than trusting older filings. Some plaintiffs’ attorneys also serve Takeda’s general counsel in Cambridge as a practical measure, but for a Delaware-incorporated subsidiary the registered agent in Delaware is the legally reliable route.
Filing fees and process server fees vary by jurisdiction. Confirm both with the clerk of the court where you plan to file before you write the check.